Pathophysiological changes of the liver-muscle axis in end-stage liver disease: what is the right target?
|Journal||Volume 85 - 2022|
|Issue||Fasc.4 - Reviews|
|Author(s)||G. Henin 1 2, N. Lanthier 1 2, G. Dahlqvist 1|
VIEW FREE PDF
(1) Service d’Hépato-gastroentérologie, Cliniques universitaires Saint-Luc, UCLouvain, Brussels, Belgium
(2) Laboratory of Gastroenterology and Hepatology, Institut de Recherche Expérimentale et Clinique, UCLouvain, Brussels, Belgium.
Liver diseases and in particular end stage liver diseases are frequently complicated by muscle modifications that are linked to worse clinical outcome. In addition, recent studies have demonstrated the negative impact of these muscle changes on liver function leading to the hypothesis of a bidirectional relationship referred in the literature as “muscle-liver axis”. In a context of evolution towards a more holistic and less organocentric vision of medicine, studying frailty, myosteatosis and sarcopenia and their underlying pathophysiological mechanisms has led to many publications in the last five years. These studies are describing several pathophysiological mechanisms, highlighting the extremely complex character of this relationship. This review aims to summarize these mechanisms as well as potential therapeutic targets, independently of liver disease etiology.
Keywords: muscle, sarcopenia, myosteatosis, end-stage liver disease, myokine, exerkine.
|The authors declare that they have no conflict of interest.|
© Acta Gastro-Enterologica Belgica.